Journal Information
Vol. 100. Issue 4.
Pages 384-391 (July - August 2024)
Share
Share
Download PDF
More article options
Visits
439
Vol. 100. Issue 4.
Pages 384-391 (July - August 2024)
Original article
Full text access
Inborn errors of immunity and its clinical significance in children with lymphoma in China: a single-center study
Visits
439
Chao Yanga,1, Nan Lib,1, Meng Zhangb, Shuang Huangb, Ling Jinb, Shu-Guang Liua, Chun-Ju Zhouc, Zhi-Gang Lia,2,
Corresponding author
ericlzg@hotmail.com

Corresponding author.
, Yan-Long Duanb,2,
Corresponding author
duanyanlong@hotmail.com

Corresponding author.
a Hematologic Disease Laboratory, Hematology Center, Beijing Key Laboratory of Pediatric Hematology Oncology, National Key Discipline of Pediatrics (Capital Medical University), Key Laboratory of Major Diseases in Children, Ministry of Education, Beijing Pediatric Research Institute, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing, China
b Medical Oncology Department, Pediatric Oncology Center, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing Key Laboratory of Pediatric Hematology Oncology, National Key Clinical Discipline of Pediatric Oncology, Key Laboratory of Major Diseases in Children, Ministry of Education, Beijing, China
c Department of Pathology, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Key Laboratory of Major Diseases in Children, Ministry of Education, Beijing, China
This item has received
Article information
Abstract
Full Text
Bibliography
Download PDF
Statistics
Figures (1)
Tables (3)
Table 1. Genetic results for 17 lymphoma patients with mutations in IEI-associated gene.
Table 2. Comparison of clinical characteristics in pediatric lymphoma patients with or without IEI in this study.
Table 3. Clinical features in 17 lymphoma patients with IEI-associated mutations.
Show moreShow less
Additional material (3)
Abstract
Objective

To investigate the incidence, clinical and genetic characteristics of pediatric lymphoma patients of China with inborn errors of immunity (IEI)-related gene mutations, which have not been fully studied.

Method

From Jan. 2020 to Mar. 2023, IEI-related genetic mutations were retrospectively explored in 108 children with lymphomas admitted to Beijing Children's Hospital by NGS. Genetic rule and clinical characteristics as well as treatment outcomes were compared between patients with or without IEI-related gene mutations.

Results

A total of 17 patients (15.7 %) harbored IEI-associated mutations, including 4 cases with X-linked lymphoproliferative syndrome (XLP), 3 cases had mutations in tumor necrosis factor receptor superfamily 13B (TNFRSF13B), 2 cases with Activated p110 syndrome (APDS). Patients with IEI all had alteration of immunocompetence with decreased levels of immunoglobulin and lymphocyte subsets. Recurrent infection existed in 41.2 % of patients. The 18-month event-free survival (EFS) and the overall response rate (ORR) of patients with IEI are significantly lower than those without IEI (33.86% vs. 73.26 %, p = 0.011; 52.94% vs. 87.91 %, p = 0.002, respectively). In addition, patients with IEI had a higher progression disease (PD) rate of 23.5 % than those without IEI of 4.4 % (p = 0.006).

Conclusion

The present study demonstrated that IEI-associated lymphomas were much more common than originally appreciated in pediatric lymphomas, and those were insensitive to treatment and more likely to progress or relapse. The genomic analysis and a thorough review of the medical history of IEI can be used to distinguish them from pediatric lymphomas without IEI, which are beneficial for the early diagnosis and direct intervention.

Keywords:
Inborn errors of immunity
Pediatric lymphoma
Genes
Mutation
Clinical features
China
Full Text
Introduction

Leukaemias, CNS tumors, and lymphomas are the pediatric cancers with the highest incidences in China. Among them, lymphoma (11.54 per million) accounts for 9.7 % of pediatric cancers, which may be an underestimated number.1,2 Pediatric and teenage lymphoma is characterized by a high degree of malignancy and aggressiveness.3 Based on the latest WHO classification (version 2022), lymphoma is divided into precursor cell neoplasms and mature malignancies of different cell lineages.4 Lymphoma in children and adolescents could be caused by infection, genetic, immunological, and physicochemical factors. At present, pediatric and adolescent lymphoma patients are treated with chemotherapy, radiotherapy, stem cell transplantation, and so on. In addition, immunotherapy has further improved the treatment outcome and prolonged the survival time of patients.5,6

Recently, new understandings of lymphoproliferative disorders associated with inborn errors of immunity (IEI, previously known as primary immunodeficiencies) and acquired immune disorders have been developed and updated in WHO-HAEM5.4 IEI comprise at least 450 inherited diseases. Arisen from intrinsic defects in immunity mostly due to genetic mutations, IEI patients are prone to recurrent infections, autoimmunity, inflammation, allergy, and malignancy.7 Lymphoma is the main cancer type in patients with IEI, especially in children.8,9 Molecular signaling abnormalities, defective immune surveillance, persistent stimulation by pathogens or transforming viruses, and other unknown mechanisms lead to an enhanced risk of lymphoma in patients with IEI.10,11 On the other hand, lymphoma can also reveal an underlying IEI. For example, lymphoma develops before the onset of PID in 11 % of cases.12

Lymphoid malignancies in patients with IEI are clinically and histologically heterogeneous, hampering prompt and accurate diagnosis of IEI.13,14 In the last decade, advances in gene sequencing technologies have facilitated the diagnosis of IEI-associated lymphoma. Pediatric lymphoma patients with heterogeneous genetic defects are much more common than previously considered.11,15,16

To date, the correlation between genetic abnormalities and clinical features in pediatric patients with IEI-associated lymphoma has not been fully investigated, especially in China. In this study, the authors retrospectively analyzed the clinical features and treatment outcomes in 17 pediatric patients with IEI-associated lymphoma.

Materials and methodsPatients

One hundred and eight patients with lymphoma treated at the Hematology Oncology Center of Beijing Children's Hospital were retrospectively enrolled in this study from Jan. 2020 to Mar. 2023. The exclusion criterion included children unable to regularly receive and complete chemotherapy or those who refuse to do tests by NGS for other reasons. Lymphomas were diagnosed by more than two pathologists, as collected and summarized their clinical and laboratory characteristics in Table S1. An evaluation system was developed and adopted for patients who were detected with genetic variations related to IEI. The evaluation system was devised as follows:

  • 1)

    IEI-group: Patients with lymphoma who had positive IEI-related mutations fulfilled the following criteria: (a)–(b).

  • 2)

    Non-IEI group: Patients with lymphoma who did not have positive IEI-related mutations.

    • (a)

      Positive IEI-relevant phenotype (characterized by autoimmunity, allergic disease, and/or immune deficiency) or positive family history of autoimmunity, allergic disease, and/or recurrent infections.

    • (b)

      Decreased concentrations of Igs (a marked decrease in the levels of at least one of the isotypes IgG, IgM, or IgA) or lymphocyte subsets(at least one of the absolute numbers of B cells, T cells, or NK cells).

Samples

DNA was extracted from the peripheral blood of the patients at diagnosis and their parents (when possible) using the QIAamp DNA Mini Kit (Qiagen, Shanghai, China) using the manufacturer's instructions. Clinical data including demographic characteristics, family history, past medical history, treatment outcomes, and clinical laboratory tests were collected, as summarized in Table S1. Informed consent for the study, including consent for the collection and the use of DNA samples for genetic analysis, was obtained from eligible children and their parents or legal guardians. The study for genetic analysis was approved under the guidelines of the ethics committee of Beijing Children's Hospital (China).

Targeted sequencing

To gain an insight into the potential lymphoma-associated IEI genes/targets, the authors designed a sequencing panel containing 152 IEI genes associated with malignancies (Table S2) based on the previous reports on lymphoma or pan-cancer IEI studies.7,10 Extracted DNA was sent to MyGenostics Company for targeted sequencing using a gene capture strategy with a GenCap custom enrichment kit (MyGenostics, China) following the manufacturer's protocol. Nucleotide-targeted sequencing was performed on the Illumina HiSeq 2000 platform (Illumina, USA). The mutations in IEI-related genes and other lymphoma susceptibility and related genes were verified by Sanger sequencing in the patients and their parents (when possible).

Mutational signature analysis

After sequencing, the raw data was saved in FASTQ file format. Illumina sequencing adapters and low-quality reads (<80 bp) were screened out using Cutadapt. The SIFT database and polymorphism phenotyping v2 were used to predict the pathogenicity of single nucleotide polymorphisms.17,18 In order to verify the pathogenic mutations, the authors collected data from the Clinvar database (https://www.ncbi.nlm.nih.gov/clinvar/) or the American College of Medical Genetics and Genomics (ACMG) guidelines.

Statistics

SPSS version 20.0 (IBM, Armonk, USA) was used for all statistical analyses of the data. The t-test and chi-square test were used to determine the differences between two numerical variables obeying normal or skewed distribution, respectively. Pearson's chi-square test was used to determine whether there was a difference in qualitative variables. Events were defined as follows: disease progression, relapse, or death for any reason. EFS was estimated by Kaplan-Meier survival analysis and compared with the log-rank test. A p value < 0.05 was considered to be statistically significant.

ResultsGeneral information

There were 27 (25 %), 38 (35 %), 18 (16 %), and 25 (23 %) patients with precursor lymphoid neoplasms, Mature B-cell neoplasms, Mature T- and NK-cell neoplasms, and HL, respectively. Among them, 24 cases were infected with EBV. There were 87 boys and 21 girls with a sex ratio of 4.35 to 1. The median age was 8.48 (range: 1–17.58) years at diagnosis (Table S1).

Mutations in IEI-related genes in children with lymphoma

All 108 children carried genes associated with immunodeficiency. The authors identified 17 pathogenic or likely pathogenic variants by SIFT, Polyphen2 software, clinvar database, and the (ACMG) guidelines. The overall diagnostic yield of 108 patients was 15.7 % (17/108). Mutations in SH2D1A, NFKB2, STAT1, PALB2, TNFRSF13B, CTLA4, PIK3CD, ELANE, POLE, MSH6, MCM4 gene were detected (Table 1).

Table 1.

Genetic results for 17 lymphoma patients with mutations in IEI-associated gene.

Patient ID  Diagnosis  Gene  Genomic variant(s)  Reference sequence  Zygosity  Inherited pattern  SIFT  PP2  MT  GERP++  ACMG scoring  ACMG pathogenicity  Source of variation  Type of mutation 
PL 1  XLP1  SH2D1A  c.145G>A/p.G49S  NM_002351  hemi  XL  PM1;PM2  UC  Mo  nonsynonymous 
PL 2  XLP1  SH2D1A  exon2 deletion  NM_002352  hemi  XL  –  –  –  PVS1+PS4+PM2  –   
PL 3  XLP1  SH2D1A  c.166dupG/p.V56Gfs*12  NM_002351  hemi  XL  –  –  –  PVS1;PM1;PM2  Mo  frameshift 
PL 4  XLP1  SH2D1A  c.164G>A/p.R55Q  NM_002351  hemi  XL  PD  PS1;PM1;PM2;PP3  LP  SP  nonsynonymous 
PL 5  CVID  NFKB2  c.1347delC/p.L450Cfs*32  NM_001077494  het  AD  –  –  –  PVS1;PM2  LP    frameshift 
PL 8  CVID  STAT1  c.778_779insC/p.Q260Pfs*24  NM_007315  Compound het  AR  –  –  –  PVS1;PM2  LP    frameshift 
    STAT1  c.770delA/p.D257Vfs*9        –  –  –  PVS1;PM2  LP    frameshift 
PL 22  CVID  PALB2  c.2748+1G>A/splicing  NM_024675  het  AD  –  PVS1;PS1;PM1;PM2    splicing 
PL 37  CVID  TNFRSF13B  c.105delC/p.E36Kfs*48  NM_012452  het  AD  –  –  –  PVS1;PS1;PM2    frameshift 
PL 39  CVID  CTLA4  c.163_164insCC/p.S55Tfs*20  NM_005214  het  AD  –  –  –  PVS1;PM1;PM2    frameshift 
PL 42  APDS  PIK3CD  c.2126C>A/p.P709H  NM_005026  het  AD  PD  PM2  UC  Fa  nonsynonymous 
PL 43  APDS  PIC3CD  c.3061G>A/p.E1021K  NM_005026  het  AD  PD  PS1;PM2;PP3  LP  Mo  nonsynonymous 
PL 57  CVID  TNFRSF13B  c.226G>A/p.G76S  NM_012452  het  AD  PD  PM1;PM2;PM5;PP3  LP    nonsynonymous 
PL 58  CVID  ELANE  c.547_548insAC/p.R183Hfs*11  NM_001972  het  AD  –  –  –  PVS1;PM1;PM2    frameshift 
PL 62  CID  POLE  c.6532–5C>T/splicing  NM_006231  Compound het  AR  –  –  –  PM2  UC    splicing 
    POLE  c.6401_6402insGC/p.D2134Efs*99        –  –  –  PVS1;PM2  LP    frameshift 
PL 84  CVID  TNFRSF13B  c.572dupA/p.D191Efs*46  NM_012452  het  AD  –  –  –  PVS1;PS1;PM1;PM2  Mo  frameshift 
PL 87  CVID  MSH6  c.2561A>T/p.K854M  NM_000179  het  AD  PD  PM2;PP3  US    nonsynonymous 
PL 108  CID  MCM4  c.2572delA/p.K858Rfs*10  NM_005914  Compound het  AR  –  –  –  PVS1;PM2  LP    frameshift 
    MCM4  c.2582delG/p.R861Pfs*7        –  –  –  PVS1;PM2  LP    frameshift 

CID, Combined Immune Deficiency; APDS, Activated p110δ syndrome; CVID, Common variable immunodeficiency; XLP1, X-linked lymphoproliferative disease; PP2, polymorphism phenotyping v2 (PD, possible damaging; B, benign); SIFT, sorting intolerant from tolerant (D, damaging; T, tolerant); clinvar (P, pathogenic; LP, likely pathogenic; CP, Conflicting interpretations of pathogenicity; US, uncertain significance); ACMG, American college of medical genetics and genomics (P, pathogenic; LP, likely pathogenic; UC, uncertain). Fa, father; Mo, mother; SP, spontaneous.

According to the 2022 update of IUIS phenotypical classification for human inborn errors of immunity,7 these patients included 4 cases with X-linked lymphoproliferative syndrome (XLPS) (4/17, 23.5 %), 8 of whom were diagnosed with common variable immunodeficiency (CVID) (8/17, 47.1 %), 2 with activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS), and an additional 2 patients with combined immunodeficiency (CID) (2/17, 11.8 %). Autosomal dominant (AD), autosomal recessive (AR), and X-linked recessive (XLR) diseases were observed in 10 (58.8 %), 3 (17.6 %), and 4 (23.5 %) patients, respectively. Hemizygous pathogenic mutations were all in SH2D1A of 4 XLP patients, and heterozygous pathogenic mutations were found in the rest of 13 patients. Among 17 positive IEI-related mutations, only six patients and their parents were verified by sanger sequencing (Supplementary Figure 1). Of the 4 XLR cases, 1 variant was de novo of patient 4. Patients 1 and 3 inherited from their mothers, respectively. Reviewing the family history of patient 3, the authors found the mother had recurrent respiratory infections during childhood. Hemizygote deletion of exon 2 had been detected in SH2D1A of patient 2, yet no pedigree validation was conducted. P.P709H and p.E1021K mutations of PIK3CD were found in patients 42 and 43 inherited from her father and mother respectively, who had suspicious clinical manifestations related to IEI. Patient 84 had a mutation of TNFRSF13B inherited from his mother, who was diagnosed with inflammatory bowel disease(IBD) (Table 2 and Table S2). The type of mutation that causes the most immune deficiency mutations in patients was frameshift (8/17, 47.06 %), followed by nonsynonymous mutation (6/17, 35.3 %) and 2 splicing mutations (Table 1).

Table 2.

Comparison of clinical characteristics in pediatric lymphoma patients with or without IEI in this study.

Clinical characteristics  Total  IEI  Non-IEI  P-value 
108  17  91   
Sex         
Male  87(80.6 %)  15(88.4 %)  72(79.1 %)  0.760 
Female  21(19.4 %)  3(11.6 %)  19(20.9 %)   
Median age (range), y  7.41(0.5–17.9)  8.75(0.5–17.9)  7.37(1–17.9)  0.218 
Stage         
Ⅰ/Ⅱ  25(23.1 %)  4(23.5 %)  21(23.1 %)  0.221 
Ⅲ/Ⅳ  83(76.9 %)  13(76.5 %)  70(76.9 %)   
EBV  23(21.3 %)  3(17.6 %)  20(22 %)  0.689 
Pathological types         
Precursor lymphoid neoplasms  27(25 %)  4(23.5 %)  23(25.3 %)  0.879 
Mature B-cell neoplasms  38(35.2 %)  7(41.2 %)  31(34.1 %)  0.537 
Mature T- and NK-cell neoplasms  18(16.7 %)  3(17.6 %)  15(16.5 %)  0.906 
Hodgkin lymphomas  25(23.1 %)  3(17.6 %)  22(24.2 %)  0.558 
Past history related to immune defects  18  10(58.8 %)  11(12.1 %)  0.000⁎⁎ 
Family history related to immune defects  8(47.1 %)  0.000⁎⁎ 
⁎⁎

Indicates a p-value of < 0.01.

Clinical characteristics of IEI related lymphoma patients

To determine whether the genotype of patients with IEI is associated with the lymphoma phenotype, the authors further compared the clinical characteristics and laboratory tests of patients in this cohort. There were 14 (88.4 %) boys and 3 (11.6 %) girls with IEI. The median age was 8.75 years (range, 0.5–17.91). 4 patients were diagnosed with precursor lymphoid neoplasms. The remaining 13 patients developed DLBCL (n = 4), BL (n = 2), HGBL (n = 1), ALCL (n = 3), and HL (n = 3). Among the disease stages, stage II (n = 4, 23.5 %), stage III (n = 7, 41.2 %), stage IV (n = 6, 35.3 %). Comparing clinical characteristics between pediatric lymphoma patients with or without IEI, pathological types, and the stage, showed no significant difference between the two groups and no correlation with IEI (all p>0.05) (Tables 2 and 3).

Table 3.

Clinical features in 17 lymphoma patients with IEI-associated mutations.

Patient ID  Gene  Lymphoma  Sex  Age  Stage  Infection  Decreased Igs(g/L)  B-cell(%)  T-cell(%)  NK-cell(%)  Indicators of immune dysregulation  Family history related to IEI 
PL 1  SH2D1A  BL  Male  12.16  Ⅱ  RRI  IgG(2.12)  Low(3.3)  –  –  Recurrent eczema  – 
PL 2  SH2D1A  HGBL  Male  5.33  III  –  IgM(0.21)  Low(12..5)  –  –  –  – 
PL 3  SH2D1A  DLBCL  Male  17.91  III  –  –  Low(9.5)  Low(35.7)  –  Allergy  Fa:+ 
PL 4  SH2D1A  DLBCL  Male  4.66  III  RRI;TB infection  IgG(4.09)  –  –  Low(6)  –   
PL 5  NFKB2  DLBCL  Male  11.5  IV  EBV and HP infection  –  Low(0.6)  –  Low(2.8)  –   
PL 8  STAT1  MCCHL  Male  II  EBV infection  IgM(0.36)  Low(12.5)  –  –  Recurrent eczema  Mo:+ 
PL 22  PALB2  ALK+-ALCL  Male  12  IV  –  IgG(4.21); IgM(0.11)  Low(10.8)  –  Low(3.1)  –  – 
PL 37  TNFRSF13B  MCCHL  Male  8.75  II  EBV infection  IgM(0.38)  Low(4.3)  Low(27.8)  Low(6.9)  –  Mo:+ 
PL 39  CTLA4  T-LBL  Male  7.58  IV  RRI  –  Low(10.5)  Low(30.3)  Low(3.2)  –  Fa:+: 
PL 42  PIK3CD  ALK+-ALCL  Female  17.9  III  –  IgM(0.37)  Low(10.2)  –  –  HLH  – 
PL 43  PIK3CD  B-LBL  Female  III  RRI  IgM(0.26)  Low(6.7)  Low(37.5)  –  ANAs+   
PL 57  TNFRSF13B  B-LBL  Female  2.5  IV  –  IgA(0.12)  –  –  Low(4.4)  Recurrent eczema  Mo:+ 
PL 58  ELANE  BL  Male  14.16  III  HP infection  IgM(0.63)  Low(5.7)  –  –  –  Mo:+ 
PL 62  POLE  NSCHL  Male  0.5  II  RRI  –  Low(7.5)  –  Low(4.4)  –  – 
PL 84  TNFRSF13B  B-LBL  Male  5.5  III  –  IgM(0.26)  Low(12.5)  Low(24.2)  –  Allergy urticaria  Mo:+ 
PL 87  MSH6  ALK+-ALCL  Male  9.08  IV  RRI; bronchopneumonia  –  –  Low(23)  Low(3)  HLH  – 
PL 108  MCM4  DLBCL  Male  12  IV  RRI;bronchopneumonia  IgG(3.59)  Low(10)  –  Low (2.1)  Allergy  – 

BL, Burkitt's lymphoma; HGBL, high-grade B lymphoma; DLBCL, diffuse large B-cell lymphoma; MCCHL, mixed cellularity classic Hodgkin lymphoma; NSCHL, nodular sclerosis Hodgkin's lymphoma; ALK+-ALCL, ALK positive anaplastic large cell lymphoma; T-LBL, T-lymphoblastic lymphoma; B-LBL, B-lymphoblastic lymphoma; RRI, recurrent respiratory infections; HLH, hemophagocytic lymphohistiocytosis; HP, helicobacter pylori; Fa, father; Mo, mother.

Regarding infections, 3 (17.6 %) patients had EBV infection, one of them had a combined HP infection. In addition, one case of tubercle bacillus infection was found in the rest people. 2(11.8 %) patients had hemophagocytic lymphohistiocytosis during the treatment. For the non-IEI group, 22 % of patients had EBV infection, which showed no significant difference between the two groups.

Regarding past history, 58.8 % (10/17) of patients in the IEI group had a positive past history of recurrent upper respiratory tract infections, eczema or allergy; and 47.1 %(8/17) of patients’ parents had positive family history of recurrent respiratory tract infections and allergic diseases, including cancer, allergic asthma, and allergic rhinitis. However, in the non-IEI group, only 8.5 % of patients had a related positive phenotype. None of the patients in the non-IEI group had a related family history. The differences between the two groups were statistically significant.

The level of immunoglobulin and immunophenotyping of peripheral blood lymphocyte subsets can provide important information for the diagnosis and treatment of immunological and hematological disorders.19 Prominently, the incidence of hypogammaglobulinemia or the decline of immunophenotyping of lymphocyte subsets were 100 % in IEI-group. For those in the non-IEI group, 5.5 % had hypogammaglobulinemia or a low level of immunophenotyping of lymphocyte subsets.

Correlation of the mutations in IEI-related genes with treatment response and prognosis

Two (11.76 %) of 17 patients with IEI achieved complete response (CR) at the end of treatment overall, and 7(41.18 %) patients achieved partial response (PR). The overall response rate (ORR) at the end of therapy exhibited a significant difference between the patients with or without IEI (52.94% vs. 87.91 %, p = 0.002, Figure 1A).

Figure 1.

Comparison of response outcomes for lymphoma patients with or without IEI. (A). Overall response (ORR) and (B) the rate of progressive/relapse at the end of treatment. CR, complete response; PR, partial response. (C) Eighteen-month Event-free survival rates of lymphoma patients. EFS of patients was 33.9 % [95 % CI, 31.3 to 36.5] for the IEI group and 73.2 % [95 % CI, 71.09–75.31] for the non-IEI group.

(0.21MB).

Notably, there were 7 patients with IEI experienced events, including 4 (23.53 %) patients with progressive disease (PD) and 3 (17.65 %) patients with disease relapses. The PD rate of patients with IEI was higher than those without IEI by 4.40 % (p = 0.006, Figure 1B). Among the patients who progressed during treatment, 2 patients were given salvage chemotherapy, one received rituximab combined chemotherapy, and another had chemotherapy and allogeneic hematopoietic stem cell transplantation(allo-HSCT). The sites of relapse in the patients were CNS and the primary tumor. Patients who progress or relapse achieve only partial remission after treatment, which only achieved PR after treatment. All patients who achieved PD or relapse only maintained PR throughout the whole follow-up period. The 18-month EFS of patients with IEI was lower than those without IEI (33.9 % [95 % CI, 31.3 to 36.5] vs. 73.2 % [95 % CI, 71.09–75.31], p = 0.011, Figure 1C), indicating that the IEI status is significantly associated with treatment response and prognosis.

Discussion

Inborn errors of immunity (IEI), with most due to genetic mutations, and comprise over 485 diseases that could present with a diverse range of disorders including infection, autoimmunity, inflammation, malignancy, and allergy.7 The incidence of IEI in international registries is 11.2 per 100,000 births,19,20,21 and the risk of developing cancer in children with IEI is about 5 to 25 %.22 However, lymphoma is the most common type of tumor. The largest study of 3658 patients with IEI registered in the United States Immune Deficiency Network (USIDNET) reported 48 % lymphoma cases.19 Based on the European Society for Immunodeficiencies (ESID) database, 8.1 % of Dutch patients with IEI had malignancy, of which lymphoma was the most frequent cancer (28.3 %) with NHL.23 Immunodeficiency is more common in lymphoma than the authors thought, especially in children and adolescents. In addition, many overlapping phenotypes of lymphoma and IEI, and all these diseases could manifest with a wide range of phenotypes of varying severities, resulting in difficult diagnosis of IEI timely and accurately, especially in resource-limited countries and regions.24 In China, there are no large cohort studies and surveys, especially in pediatric lymphomas. Therefore, the study of IEI-associated lymphomas has important clinical significance.

This study retrospectively analyzed IEI-associated mutations, clinical characteristics, and treatment outcomes of pediatric lymphoma patients with IEI. Pediatric IEI-associated lymphoma showed particular genetic background, and clinical and biological features at diagnosis, compared with patients without IEI.

The data showed that IEI occurred in 15.7 % (17/108) of the Chinese pediatric lymphoma cohort, which approached to that 17 % (17/100) of Turkish pediatric oncology centers.25 Of the positive cases, the most frequent IEI type were CVID and XLP1. IEI diseases are genetically and phenotypically heterogeneous disorders,8 the data of mutations indicates similar results. Among IEI-associated genes,7,9NFKB2,26PIK3CD, STAT1,27PALB2, SH2D1A,28TNFRSF13B,10MSH6, CTLA4 genes had previously been reported in lymphoma or hematological malignancies genomic studies or are lymphoma susceptibility genes. By sanger sequencing, 66.7 % (6/9) of children were inherited from parents carriers. Therefore, necessary fertility guidance of immunodeficiency gene screening is helpful for those families.

In IEI cases, the risk of developing lymphoma, particularly NHL, with about 40–50 % of those diagnosed with DLBCL.6,11 In this study, a diagnosis of IEI was made in 82.4 % (14/17) children of NHL, especially mature b-cell neoplasms (41.2%). In addition, EBV infections are known to be related to lymphomagenesis in patients with IEI.10,36 There were only 3 patients in the IEI group who were EBV+, lower than the non-IEI group. Pan-Hammarström et al. reported that a different mutational profile may exist in the EBV+ lymphoma genome from that in IEI patients.10

Among the many types of IEI, genetic defects could cause abnormalities in the differentiation and development of T and B cells.7 Abnormalities occurring at different stages often lead to non-specific clinical manifestations represented by recurrent/specific infections. The authors found that patients with IEI had apparent alteration of immunocompetence of low immunoglobulin or decreased T, B, and NK lymphocyte subsets, which might help to identify IEI patients in pediatric lymphomas. Most patients were observed to have a previous history of recurrent respiratory infections, eczema, and changes in allergy. Therefore, initial screening of IEI in lymphoma can be determined by laboratory tests that are less technically demanding and more available, such as complete blood count, lymphocyte subsets, immunoglobulin profile, in addition to family surveys.29

Despite the high rate of cure in lymphoma, disease progression/relapse occurred in cases with lymphoma developing on a background of IEI considerably increased. The data also revealed that the rate of EFS was significantly lower in the IEI group than in the group without IEI. The most important problem is the high occurrence rate of treatment-related toxicity, like mucositis, infection, and bone marrow suppression. As a result, the tumors of these patients had become refractory with reduced dosages of chemoradiotherapy, which affected the treatment outcome. So far the team has reported the treatment of Hodgkin's lymphoma (HL) in pediatric patients with titin (TTN) gene mutation and heart failure. In this case, the authors explored to use brentuximab vedotin (BV) plus chemotherapy without anthracyclines to treat one pediatric HL patient with TTN mutation. At the end of 4 cycles of BV and six courses of chemotherapy, with complete remission achieved, the tumor was reduced by 85 %.30 Thus, hypotoxicity and more effective targeted immunotherapy may improve the treatment success.

NGS was used to sequence highly suspected lymphoma patients, which was cost-effective and time-efficient.13 Notably, given the economic considerations of some families, genetic data were acquired from only 152 IEI genes associated with tumorigenesis in this study, which probably caused most of the information on the whole exome and genome to be overlooked. Whereas a public interest project from 2001 by Hong Kong University pointed to targeted gene sequencing should remain the first-tier genetic test for children to suspect common IEI.20 Therefore, expanding gene panel or selecting WES/WGS is a question worth considering, especially the patients in economically underdeveloped areas.

In conclusion, pediatric oncologists should be aware of the increasing trend of lymphoma patients with IEI and make early identification and diagnosis of IEI patients through clinical symptoms, family history, and immune-related laboratory tests. For diagnosed patients, adjusting treatment regimens timely, and targeted immunotherapy may be the new directions in the future. Therefore, pediatricians are required to master certain knowledge of immunology and genetics to carry out correct genetic counseling for children undergoing genetic testing, including follow-up birth planning and sibling screening. Exploring the genetic characteristics further and achieving sustained resolution of IEI-associated lymphoma remains a challenge, and further prospective studies with larger sample sizes and extended follow-up will be required.

References
[1]
X. Ni, Z. Li, X. Li, X. Zhang, G. Bai, Y. Liu, et al.
Socioeconomic inequalities in cancer incidence and access to health services among children and adolescents in China: a cross-sectional study.
Lancet, 400 (2022), pp. 1020-1032
[2]
C.K. Li, J. Tang, H. Zheng, J. Fang, X. Sun.
Treatment of childhood cancer in China: current status and future direction.
Pediatr Investig, 4 (2020), pp. 153-156
[3]
S.M. Jaglowski, E. Linden, A.M. Termuhlen, J.M. Flynn.
Lymphoma in adolescents and young adults.
Semin Oncol, 36 (2009), pp. 381-418
[4]
R. Alaggio, C. Amador, I. Anagnostopoulos, A.D. Attygalle, I.B. Araujo, E. Berti, et al.
The 5th edition of the World Health Organization classification of haematolymphoid tumours: lymphoid neoplasms.
Leukemia, 36 (2022), pp. 1720-1748
[5]
D. Gómez-Almaguer, O. González-Llano, V. Jiménez-Antolinez, A. Gómez-De León.
Treatment of classical Hodgkin's lymphoma in children and adolescents.
Expert Opin Pharmacother, 20 (2019), pp. 1227-1234
[6]
M.J. Barth, Y. Chu, P.J. Hanley, M.S. Cairo.
Immunotherapeutic approaches for the treatment of childhood, adolescent and young adult non-Hodgkin lymphoma.
Br J Haematol, 173 (2016), pp. 597-616
[7]
S.G. Tangye, W. Al-Herz, A. Bousfiha, C. Cunningham-Rundles, J.L. Franco, S.M. Holland, et al.
Human inborn errors of immunity: 2022 update on the classification from the International Union of Immunological Societies Expert Committee.
J Clin Immunol, 42 (2022), pp. 1473-1507
[8]
R. Kebudi, A. Kiykim, M.K. Sahin.
Primary immunodeficiency and cancer in children; a review of the literature.
Curr Pediatr Rev, 15 (2019), pp. 245-250
[9]
H. Abolhassani, Y. Wang, L. Hammarström, Q. Pan-Hammarström.
Hallmarks of cancers: primary antibody deficiency versus other inborn errors of immunity.
Front Immunol, 12 (2021),
[10]
X. Ye, P.J. Maglione, C. Wehr, X. Li, Y. Wang, H. Abolhassani, et al.
Genomic characterization of lymphomas in patients with inborn errors of immunity.
Blood Adv, 6 (2022), pp. 5403-5414
[11]
B. Gathmann, N. Mahlaoui CEREDIH, L. Gérard, E. Oksenhendler, K. Warnatz, et al.
Clinical picture and treatment of 2212 patients with common variable immunodeficiency.
J Allergy Clin Immunol, 134 (2014), pp. 116-126
[12]
D. Hanahan, R.A. Weinberg.
Hallmarks of cancer: the next generation.
[13]
Y. Natkunam, D. Gratzinger, A. Chadburn, J.R. Goodlad, J.K. Chan, J. Said, et al.
Immunodeficiency-associated lymphoproliferative disorders: time for reappraisal?.
Blood, 132 (2018), pp. 1871-1878
[14]
K.W. Chan, C.Y. Wong, D. Leung, X. Yang, S.F. Fok, P.H. Mak, et al.
Targeted gene sanger sequencing should remain the first-tier genetic test for children suspected to have the five common X-linked inborn errors of immunity.
Front Immunol, 13 (2022),
[15]
E. Perez.
Future of therapy for inborn errors of immunity.
Clin Rev Allergy Immunol, 63 (2022), pp. 75-89
[16]
P.C. Ng, S. Henikoff.
SIFT: predicting amino acid changes that affect protein function.
Nucleic Acids Res, 31 (2003), pp. 3812-3814
[17]
I.A. Adzhubei, S. Schmidt, L. Peshkin, V.E. Ramensky, A. Gerasimova, P. Bork, et al.
A method and server for predicting damaging missense mutations.
Nat Methods, 7 (2010), pp. 248-249
[18]
Y. Ding, L. Zhou, Y. Xia, W. Wang, Y. Wang, L. Li, et al.
Reference values for peripheral blood lymphocyte subsets of healthy children in China.
J Allergy Clin Immunol, 142 (2018), pp. 970-973
[19]
P.C. Mayor, K.H. Eng, K.L. Singel, S.I. Abrams, K. Odunsi, K.B. Moysich, et al.
Cancer in primary immunodeficiency diseases: cancer incidence in the United States Immune Deficiency Network Registry.
J Allergy Clin Immunol, 141 (2018), pp. 1028-1035
[20]
B.M. Jonkman-Berk, J.M. van den Berg, I.J. Ten Berge, R.G. Bredius, G.J. Driessen, V.A. Dalm, et al.
Primary immunodeficiencies in the Netherlands: national patient data demonstrate the increased risk of malignancy.
Clin Immunol, 156 (2015), pp. 154-162
[21]
S. Renzi, K.P. Langenberg-Ververgaert, N. Waespe, S. Ali, J. Bartram, O. Michaeli, et al.
Primary immunodeficiencies and their associated risk of malignancies in children: an overview.
Eur J Pediatr, 179 (2020), pp. 689-697
[22]
K. Salavoura, A. Kolialexi, G. Tsangaris, A. Mavrou.
Development of cancer in patients with primary immunodeficiencies.
Anticancer Res, 28 (2008), pp. 1263-1269
[23]
L. Kobrynski, R.W. Powell, S. Bowen.
Prevalence and morbidity of primary immunodeficiency diseases, United States 2001-2007.
J Clin Immunol, 34 (2014), pp. 954-961
[24]
V. Knight, J.R. Heimall, H. Chong, S.L. Nandiwada, K. Chen, M.G. Lawrence, et al.
A toolkit and framework for optimal laboratory evaluation of individuals with suspected primary immunodeficiency.
J Allergy Clin Immunol Pract, 9 (2021), pp. 3293-3307
[25]
H.G. Tanyildiz, H. Dincaslan, G. Yavuz, E. Unal, A. Ikinciogulları, F. Dogu, et al.
Lymphoma secondary to congenital and acquired immunodeficiency syndromes at a Turkish Pediatric Oncology Center.
J Clin Immunol, 36 (2016), pp. 667-676
[26]
Y. Zhang, L. Tong, S. Chen, W. Wu, L. Wang.
Analysis of NFKB2mediated regulation of mechanisms underlying the development of Hodgkin's lymphoma.
Mol Med Rep, 17 (2018), pp. 8129-8136
[27]
S.E. Henrickson, J.G. Dolan, L.R. Forbes, A. Vargas-Hernández, S. Nishimura, S. Okada, L.S. Kersun, G.M. Brodeur, J.R. Heimall.
Gain-of-function STAT1 mutation with familial lymphadenopathy and Hodgkin lymphoma.
Front Pediatr, 7 (2019), pp. 160
[28]
J. Sumegi, D. Huang, A. Lanyi, J.D. Davis, T.A. Seemayer, A. Maeda, et al.
Correlation of mutations of the SH2D1A gene and Epstein Barr virus infection with clinical phenotype and outcome in X-linked lymphoproliferative disease.
Blood, 96 (2000), pp. 3118-3125
[29]
D. Leung, G.T. Chua, A.V. Mondragon, Y. Zhong, L. Nguyen-Ngoc-Quynh, K. Imai, et al.
Current perspectives and unmet needs of primary immunodeficiency care in Asia Pacific.
Front Immunol, 11 (2020), pp. 1605
[30]
Y. Li, L. Liu, H. Sun, N. Li, S. Huang, A. Olinger, et al.
Complete remission of Hodgkin's lymphoma in a pediatric patient with TTN gene mutation treated with brentuximab vedotin combined chemotherapy without anthracyclines: a case report.
Front Oncol, 12 (2022),

These authors share first authorship.

These authors contributed equally to this work as co-corresponding authors.

Copyright © 2024. Sociedade Brasileira de Pediatria
Idiomas
Jornal de Pediatria (English Edition)
Article options
Tools
Supplemental materials
en pt
Taxa de publicaçao Publication fee
Os artigos submetidos a partir de 1º de setembro de 2018, que forem aceitos para publicação no Jornal de Pediatria, estarão sujeitos a uma taxa para que tenham sua publicação garantida. O artigo aceito somente será publicado após a comprovação do pagamento da taxa de publicação. Ao submeterem o manuscrito a este jornal, os autores concordam com esses termos. A submissão dos manuscritos continua gratuita. Para mais informações, contate assessoria@jped.com.br. Articles submitted as of September 1, 2018, which are accepted for publication in the Jornal de Pediatria, will be subject to a fee to have their publication guaranteed. The accepted article will only be published after proof of the publication fee payment. By submitting the manuscript to this journal, the authors agree to these terms. Manuscript submission remains free of charge. For more information, contact assessoria@jped.com.br.
Cookies policy Política de cookies
To improve our services and products, we use "cookies" (own or third parties authorized) to show advertising related to client preferences through the analyses of navigation customer behavior. Continuing navigation will be considered as acceptance of this use. You can change the settings or obtain more information by clicking here. Utilizamos cookies próprios e de terceiros para melhorar nossos serviços e mostrar publicidade relacionada às suas preferências, analisando seus hábitos de navegação. Se continuar a navegar, consideramos que aceita o seu uso. Você pode alterar a configuração ou obter mais informações aqui.